Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, parallel arm, 12-week study to evaluate the efficacy and safety of ezetimibe 10 mg when added to atorvastatin 10 mg versus titration to atorvastatin 20 mg and to 40 mg in elderly patients with hypercholesterolaemia at high risk for CHD

Next Previous
X
Search
Trial Profile

A multicenter, randomized, double-blind, parallel arm, 12-week study to evaluate the efficacy and safety of ezetimibe 10 mg when added to atorvastatin 10 mg versus titration to atorvastatin 20 mg and to 40 mg in elderly patients with hypercholesterolaemia at high risk for CHD

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe (Primary) ; Atorvastatin
  • Indications Coronary disorders; Hypercholesterolaemia; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms ZETELD
  • Sponsors Merck & Co; Organon

    • Most Recent Events

    • 01 Mar 2010 Results have been published in the American Journal of Cardiology.
    • 13 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Actual patient number (1053) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top